IRWD
IRONWOOD PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.03
+6.90%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$4.32
From 52W high−25.23%
Volume4.98M
Market cap$665.92M
P/E (TTM)5.1x
P/S (TTM)1.7x
Div yield—
Key dataNov 5, 2026
Open
$4.32
From 52W high
−25.23%
Volume
4.98M
Market cap
$665.92M
ValuationView details →
P/E (Fwd)
3.1x
EV/EBITDA
4.1x
P/E (TTM)
5.1x
RSI (14)
61.8
MomentumView details →
1D Return
+6.90%
YTD Return
+19.88%
SummaryUpdated Jun 1, 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a Boston-based healthcare company founded in 1998 that specializes in developing and commercializing treatments for gastrointestinal disorders. Originally incorporated as Microbia, Inc., the company changed its name to Ironwood Pharmaceuticals in 2008 and went public in 2010. The company has evolved from a research-focused biotechnology firm into a commercial-stage pharmaceutical company with a primary focus on gastrointestinal therapeutics, anchored by its flagship product LINZESS and a promising pipeline candidate apraglutide for rare diseases.
Similar companies
Latest newsMore news →
Ironwood Pharmaceuticals reported third-quarter 2026 revenue of $133.0 million, net income of $59.8 million and diluted EPS of $0.36.20h agoIRONWOOD PHARMACEUTICALS INC raised its full-year 2026 financial guidance, citing continued U.S. LINZESS net sales growth and strong third-quarter performance.20h agoIronwood Pharmaceuticals said Thomas McCourt will retire as chief executive officer and leave the board of directors, effective December 31, 2026.21d ago